The Filing Desk

Nephros vs Jin Medical International

Nephros NEPH · Jin Medical International ZJYL · Health Care Equipment

Jin Medical International reported revenue of $21 million in fiscal 2025, about the same as Nephros' $19 million in fiscal 2025. Nephros' revenue grew 32.7% in its latest year, and Jin Medical International's fell 12.0%. Nephros had an operating margin of 6.1%, against 2.9% at Jin Medical International. Their fiscal years end in different months (December 31 and September 30), so the periods don't line up exactly.

Side by side

NephrosJin Medical International
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Sep 30, 2025
Revenue$19M$21M
Revenue growth32.7%−12.0%
Revenue growth a year, last 5 years16.9%—
Gross margin61.9%29.2%
Operating margin6.1%2.9%
Net margin6.3%5.8%
Free cash flow—−$4M
Free cash flow margin—−18.0%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count3.5%0.1%
Last close$2.84$3.34
P/E at the last close15.8×—
Insider trades, last 12 monthsbought $22,075, sold $0—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
NephrosJin Medical International
Operating margin
Percent of revenue
NephrosJin Medical International
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
NephrosJin Medical International

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Nephros and Jin Medical International pages.